Abstract
598 THE LANCET • Vol 357 • February 24, 2001 25 Falutz J, Turcot D. Considerations in the development of a case definition for HIV/HAART-associated lipodystrophy syndrome. San Diego: First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 1999: (abstr 21). 26 Muurahainen N, Falutz J, Santos G, et al. The SALSA (selfascertained lipodystrophy syndrome assessment) cohort abnormalities in cases compared to controls. San Diego: First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 1999 (abstr 22). 27 Muurahainen N, Pettit R, Kotler D, et al. Abnormalities in HIVassociated lipodystrophy syndrome that vary by weight status. San Diego: First International Workshop on Adverse drug Reactions and Lipodystrophy in HIV, 1999: (abstr 63). 28 Flynn MA, Nolph GB, Baker AS, et al. Total body potassium in aging humans: a longitudinal study. Am J Clin Nutr 1989; 50: 713–17. 29 Shimokata H, Tobin JD, Muller DC, et al. Studies in the distribution of body fat: effects of the age, sex and obesity. J Gerontol 1989; 44: 66–73. 30 Schwartz RS, Shuman WP, Bradbury VL, et al. Body fat distribution in healthy young and older men. J Gerontol 1990; 45: 181–85. 31 Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 2493–505. 32 Silva M, Skolnik P, Gorbach S, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998; 12: 1645–51. 33 Carbonnel F, Maslo C, Beaugerie L, et al. Effect of indinavir on HIVrelated wasting. AIDS 1998; 12: 1777–84. 34 Pernerstorfer-Schoen H, Schindler K, Parschalk B, et al. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. AIDS 1999; 13: 2389–96.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
